Pharmacological studies of 2-(3-(3-(1-piperidinylmethyl)-phenoxy)propylamino)-4 (3H)-quinazolinone (NO-794), a new histamine H2-receptor antagonist

Jpn J Pharmacol. 1986 Oct;42(2):229-35. doi: 10.1254/jjp.42.229.

Abstract

The pharmacological profile of a new histamine H2-receptor antagonist, 2-(3-(3-(1-piperidinylmethyl)phenoxy)propylamino)-4 (3H)-quinazolinone (NO-794), was studied. NO-794 was a potent and selective histamine H2-receptor antagonist in the guinea-pig atria and gastric mucosal cells. NO-794 (1 X 10(-5) M) did not interact with H1-, muscarinic and beta 1-receptors. In guinea-pig atria, antagonism of NO-794 was unsurmountable. The onset of action of NO-794 was slow, and this antagonism was apparently irreversible not only on the guinea-pig atria but also on the gastric mucosal cells. In addition, NO-794 inhibited gastric acid secretion in pylorus ligated rats when administered intraduodenally. These results indicate that NO-794 is a powerful and unique histamine H2-receptor antagonist and may be useful in the treatment of peptic ulcer.

MeSH terms

  • Animals
  • Cyclic AMP / biosynthesis
  • Gastric Acid / drug effects
  • Gastric Acid / metabolism
  • Gastric Mucosa / drug effects
  • Gastric Mucosa / metabolism
  • Guinea Pigs
  • Heart Rate / drug effects
  • Histamine H2 Antagonists*
  • In Vitro Techniques
  • Ligation
  • Male
  • Phenoxypropanolamines
  • Pylorus
  • Quinazolines / pharmacology*
  • Quinazolinones
  • Ranitidine / pharmacology

Substances

  • Histamine H2 Antagonists
  • Phenoxypropanolamines
  • Quinazolines
  • Quinazolinones
  • NO 794
  • Ranitidine
  • Cyclic AMP